5Pedro de Noronha Pissarra. Changes in the business of culture.Nature Biotechnology, 2004, 22(11):1355 - 1356. 被引量：1
6From chrysalis to butterfly: how far has pharma come?. 2005,http ://www. imshealth. com/vgn/images/portal/cit-40000873/53/55/74033576SCRIP% 20rev-.pdf ( accessed October 20,2005). 被引量：1
7CDER biologic approvals beginning in 2004-9,2005. CDERD rug and Biologic Approval Reports. http://www. fda. gov/cder/rdmt/default.htm( accessed October 20,2005 ). 被引量：1
8IMS Marketing Research Report. 2004, http ://pubs. acs. org/cen/coverstory/8249/8249pharmareview. html ( ac-cessed October 20,2005 ). 被引量：1
8Munos B. Lessons from 60 years of phannaceutical innovation[ J].Nat Rev Drug Discov, 2009, 8( 12) :959-68. 被引量：1
9Paul SM, Mytelka DS,Dunwiddie CT, et al . How to improveR&D productivity: the pharmaceutical industry's grand challenge[J]. Nat Rev Drug Discov, 2010, 9(3) :203-14. 被引量：1
